Andreas Zwergal Selected Research

Aminopyridines

1/2019	Advances in pharmacotherapy of vestibular and ocular motor disorders.
2/2017	Aminopyridines for the treatment of neurologic disorders.
4/2015	Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.
7/2009	Medical treatment of vestibular disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas Zwergal Research Topics

Disease

4	Vertigo (Positional Vertigo) 10/2021 - 01/2010
3	Type 2 Episodic Ataxia 04/2015 - 04/2007
2	Vestibular Neuronitis (Vestibular Neuritis) 01/2022 - 07/2009
2	Dizziness (Lightheadedness) 10/2021 - 02/2020
2	Nervous System Diseases (Neurological Disorders) 02/2017 - 04/2007
1	Parkinson Disease (Parkinson's Disease) 01/2022
1	Cognitive Dysfunction 01/2020
1	Alzheimer Disease (Alzheimer's Disease) 01/2019
1	Tauopathies 01/2019
1	Motor Disorders 01/2019
1	Brain Diseases (Brain Disorder) 01/2018
1	Tremor (Tremors) 01/2017
1	Hallucinations (Hallucination) 08/2016
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 08/2016
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 08/2016
1	Benign Paroxysmal Positional Vertigo 04/2015
1	Cerebellar Ataxia (Dysmetria) 04/2015
1	Cerebellar Diseases (Cerebellar Syndrome) 04/2015
1	Meniere Disease (Menieres Disease) 04/2015
1	Migraine Disorders (Migraine) 04/2015
1	Body Weight (Weight, Body) 01/2015
1	Neoplasms (Cancer) 02/2014
1	Alcoholism (Alcohol Abuse) 03/2012
1	Inflammation (Inflammations) 12/2009
1	Atherosclerosis 01/2007
1	Sepsis (Septicemia) 06/2003

Drug/Important Bio-Agent (IBA)

4	AminopyridinesIBA 01/2019 - 07/2009
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 12/2009
2	4-Aminopyridine (4 Aminopyridine)FDA Link 02/2017 - 04/2015
2	Potassium Channel Blockers (Blockers, Potassium Channel)IBA 02/2017 - 07/2009
2	acetylleucineIBA 04/2015 - 01/2015
2	Betahistine (Serc)IBA 04/2015 - 07/2009
2	Carbamazepine (Tegretol)FDA LinkGeneric 04/2015 - 07/2009
2	Biological ProductsIBA 02/2014 - 01/2010
2	CCAAT-Enhancer-Binding Protein-betaIBA 12/2009 - 06/2003
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2022
1	Amyloid (Amyloid Fibrils)IBA 01/2020
1	ConvulsantsIBA 01/2019
1	3- (1,3- benzodioxol- 5- yl)- 5- (3- bromophenyl)- 1H- pyrazoleIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	AmifampridineIBA 02/2017
1	Glucose (Dextrose)FDA LinkGeneric 01/2017
1	rasagiline (Azilect)FDA Link 08/2016
1	Acetazolamide (Diamox)FDA LinkGeneric 04/2015
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 04/2015
1	Anticonvulsants (Antiepileptic Drugs)IBA 04/2015
1	Antidepressive Agents (Antidepressants)IBA 04/2015
1	AntiemeticsIBA 04/2015
1	Metoprolol (Toprol-XL)FDA LinkGeneric 04/2015
1	Vitamin D FDA LinkGeneric 04/2015
1	Leucine (L-Leucine)FDA Link 01/2015
1	PlacebosIBA 01/2015
1	RacloprideIBA 03/2012
1	Dopamine (Intropin)FDA LinkGeneric 03/2012
1	NF-kappa B (NF-kB)IBA 12/2009
1	oxcarbamazepineIBA 07/2009
1	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2009
1	Calcium Channels (Calcium Channel)IBA 04/2007
1	oxidized low density lipoproteinIBA 01/2007
1	Interleukin-8 (Interleukin 8)IBA 06/2003

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2019 - 01/2010
2	Therapeutics 10/2021 - 01/2019
1	Deep Brain Stimulation 01/2022
1	Occupational Therapy (Therapy, Occupational) 02/2020
1	Combined Modality Therapy 02/2020